These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 34055657)
1. The Effects of Fecal Microbiota Transplantation on the Symptoms and the Duodenal Neurogenin 3, Musashi 1, and Enteroendocrine Cells in Patients With Diarrhea-Predominant Irritable Bowel Syndrome. Mazzawi T; El-Salhy M; Lied GA; Hausken T Front Cell Infect Microbiol; 2021; 11():524851. PubMed ID: 34055657 [TBL] [Abstract][Full Text] [Related]
2. The kinetics of gut microbial community composition in patients with irritable bowel syndrome following fecal microbiota transplantation. Mazzawi T; Lied GA; Sangnes DA; El-Salhy M; Hov JR; Gilja OH; Hatlebakk JG; Hausken T PLoS One; 2018; 13(11):e0194904. PubMed ID: 30427836 [TBL] [Abstract][Full Text] [Related]
3. Clinical response to fecal microbiota transplantation in patients with diarrhea-predominant irritable bowel syndrome is associated with normalization of fecal microbiota composition and short-chain fatty acid levels. Mazzawi T; Hausken T; Hov JR; Valeur J; Sangnes DA; El-Salhy M; Gilja OH; Hatlebakk JG; Lied GA Scand J Gastroenterol; 2019 Jun; 54(6):690-699. PubMed ID: 31190584 [No Abstract] [Full Text] [Related]
4. Changes in duodenal enteroendocrine cells in patients with irritable bowel syndrome following dietary guidance. Mazzawi T; El-Salhy M Exp Biol Med (Maywood); 2017 Jul; 242(13):1355-1362. PubMed ID: 28737477 [TBL] [Abstract][Full Text] [Related]
5. Changes in colonic enteroendocrine cells of patients with irritable bowel syndrome following fecal microbiota transplantation. Mazzawi T; Hausken T; El-Salhy M Scand J Gastroenterol; 2022 Jul; 57(7):792-796. PubMed ID: 35156893 [TBL] [Abstract][Full Text] [Related]
6. Abnormal Uroguanylin Immunoreactive Cells Density in the Duodenum of Patients with Diarrhea-Predominant Irritable Bowel Syndrome Changes following Fecal Microbiota Transplantation. Mazzawi T; Eikrem Ø; Lied GA; Hausken T Gastroenterol Res Pract; 2020; 2020():3520686. PubMed ID: 32089675 [TBL] [Abstract][Full Text] [Related]
7. Reduction in duodenal endocrine cells in irritable bowel syndrome is associated with stem cell abnormalities. El-Salhy M; Hatlebakk JG; Hausken T World J Gastroenterol; 2015 Aug; 21(32):9577-87. PubMed ID: 26327765 [TBL] [Abstract][Full Text] [Related]
8. Abnormalities in ileal stem, neurogenin 3, and enteroendocrine cells in patients with irritable bowel syndrome. El-Salhy M; Gilja OH BMC Gastroenterol; 2017 Aug; 17(1):90. PubMed ID: 28764761 [TBL] [Abstract][Full Text] [Related]
9. Enteroendocrine, Musashi 1 and neurogenin 3 cells in the large intestine of Thai and Norwegian patients with irritable bowel syndrome. El-Salhy M; Patcharatrakul T; Hatlebakk JG; Hausken T; Gilja OH; Gonlachanvit S Scand J Gastroenterol; 2017 Dec; 52(12):1331-1339. PubMed ID: 28853300 [TBL] [Abstract][Full Text] [Related]
10. Changes in fecal short-chain fatty acids following fecal microbiota transplantation in patients with irritable bowel syndrome. El-Salhy M; Valeur J; Hausken T; Gunnar Hatlebakk J Neurogastroenterol Motil; 2021 Feb; 33(2):e13983. PubMed ID: 32945066 [TBL] [Abstract][Full Text] [Related]
11. The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors. Lin H; Guo Q; Wen Z; Tan S; Chen J; Lin L; Chen P; He J; Wen J; Chen Y Microb Cell Fact; 2021 Dec; 20(1):233. PubMed ID: 34963452 [TBL] [Abstract][Full Text] [Related]
13. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. Johnsen PH; Hilpüsch F; Cavanagh JP; Leikanger IS; Kolstad C; Valle PC; Goll R Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):17-24. PubMed ID: 29100842 [TBL] [Abstract][Full Text] [Related]
14. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. Halkjær SI; Christensen AH; Lo BZS; Browne PD; Günther S; Hansen LH; Petersen AM Gut; 2018 Dec; 67(12):2107-2115. PubMed ID: 29980607 [TBL] [Abstract][Full Text] [Related]
15. Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short- and Long-term Results From a Placebo-Controlled Randomized Trial. Holvoet T; Joossens M; Vázquez-Castellanos JF; Christiaens E; Heyerick L; Boelens J; Verhasselt B; van Vlierberghe H; De Vos M; Raes J; De Looze D Gastroenterology; 2021 Jan; 160(1):145-157.e8. PubMed ID: 32681922 [TBL] [Abstract][Full Text] [Related]
16. Relief of irritable bowel syndrome by fecal microbiota transplantation is associated with changes in diversity and composition of the gut microbiota. Huang HL; Chen HT; Luo QL; Xu HM; He J; Li YQ; Zhou YL; Yao F; Nie YQ; Zhou YJ J Dig Dis; 2019 Aug; 20(8):401-408. PubMed ID: 31070838 [TBL] [Abstract][Full Text] [Related]
17. Responses to faecal microbiota transplantation in female and male patients with irritable bowel syndrome. El-Salhy M; Casen C; Valeur J; Hausken T; Hatlebakk JG World J Gastroenterol; 2021 May; 27(18):2219-2237. PubMed ID: 34025075 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of Fecal Microbiota Transplantation in Irritable Bowel Syndrome Patients: An Updated Systematic Review and Meta-Analysis. Elhusein AM; Fadlalmola HA Gastroenterol Nurs; 2022 Jan-Feb 01; 45(1):11-20. PubMed ID: 35108241 [TBL] [Abstract][Full Text] [Related]
19. Bifidobacterium-Rich Fecal Donor May Be a Positive Predictor for Successful Fecal Microbiota Transplantation in Patients with Irritable Bowel Syndrome. Mizuno S; Masaoka T; Naganuma M; Kishimoto T; Kitazawa M; Kurokawa S; Nakashima M; Takeshita K; Suda W; Mimura M; Hattori M; Kanai T Digestion; 2017; 96(1):29-38. PubMed ID: 28628918 [TBL] [Abstract][Full Text] [Related]